Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043807 · ClinicalTrials.gov registry record · Phase 2
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03043807 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 26 participants.
The verdict
NCT03043807, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (\~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of chemotherapy, (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade will be the same throughout the course of treatment.
Interventions
- DRUG Docetaxel
- RADIATION Radiation
- DRUG Abiraterone Acetate
- DRUG Bicalutamide
- DRUG Leuprolide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043807
The ClinicalTrials.gov registry entry for NCT03043807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT03043807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043807 about?
NCT03043807 is a clinical study titled "A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy". To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (\~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of chemotherapy, (2nd) definitive local tumor control with adjuvant radiati...
What is the current status of trial NCT03043807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-02-22. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT03043807?
The interventions under investigation include: Docetaxel (DRUG), Radiation (RADIATION), Abiraterone Acetate (DRUG), Bicalutamide (DRUG), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT03043807?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.